Emerging Drugs and Targets for Parkinson’s Disease
Affecting over 1.5 million people across the world, Parkinson's disease is a progressive neurological condition characterized, in part, by the loss of dopaminergic neurons in the substantia nigra pars compacta. It affects 1.5% of the global population over 65 years of age. As life expectancy is increasing, over the next few years the number of patients with Parkinson´s disease will grow exponentially. To date, there are no available treatments that are capable of curing Parkinson´s disease, and the current goal of therapy, dopamine replacement strategies, is to reduce symptoms. After several years of disease progression, treatment is complicated by the onset of motor fluctuations and dyskinesias. This information reveals the great importance and social need of finding an effective therapeutic intervention for Parkinson´s disease.
This exemplary new book reviews some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets currently undergoing the validation process to try to reach the Parkinson´s drug market in the next few years as potential disease modifying drugs. Providing up to date and comprehensive coverage, this book is essential reading for researchers working in academia and industry in any aspect of medicinal chemistry or drug discovery.
Emerging Drugs and Targets for Parkinson’s Disease, The Royal Society of Chemistry, 2013.
Download citation file:
Digital access
Print format
Table of contents
-
Parkinson’s Disease: Symptoms, Unmet Needs and New Therapeutic Targetsp3-25ByMónica M. Kurtis;Mónica M. KurtisMovement Disorders Unit, Department of NeurologyHospital Ruber InternacionalMadrid, Spain[email protected]Search for other works by this author on:Pablo Martinez‐MartínPablo Martinez‐MartínArea of Applied EpidemiologyNational Centre of Epidemiology and CIBERNED, Carlos III Institute of HealthMadrid, SpainAlzheimer Disease Research UnitCIEN Foundation, Carlos III Institute of Health, Alzheimer Center Reina Sofia FoundationMadrid, SpainSearch for other works by this author on:
-
CHAPTER 2: Molecular Pathogenesis and Pathophysiology of Parkinson’s Disease: New Targets for New Therapiesp26-57ByJosé G. Castaño;José G. CastañoDepartamento de Bioquímica, Instituto de Investigaciones Biomédicas “Alberto Sols”, Facultad de MedicinaUniversidad Autónoma de MadridSpainCentro de Investigación Biomédica en Red sobre Enfermedades NeurodegenerativasMadridSpain[email protected]Search for other works by this author on:Carmen González;Carmen GonzálezDepartamento de Farmacologia, Facultad de MedicinaUniversidad de Castilla‐La ManchaAlbaceteSpainSearch for other works by this author on:José A. Obeso;José A. ObesoCentro de Investigación Biomédica en Red sobre Enfermedades NeurodegenerativasMadridSpain[email protected]Laboratorio de Trastornos del Movimiento, Centro de Investigación Médica AplicadaUniversity of NavarraPamplonaSpainSearch for other works by this author on:Manuel RodriguezManuel RodriguezCentro de Investigación Biomédica en Red sobre Enfermedades NeurodegenerativasMadridSpain[email protected]Laboratory of Neurobiology and Experimental Neurology, Department of Physiology, Faculty of MedicineUniversity of La LagunaTenerifeCanary IslandsSearch for other works by this author on:
-
CHAPTER 3: Dopaminergic Treatments for Parkinson’s Disease: Light and Shadowsp61-82ByNicola SimolaNicola SimolaDepartment of Biomedical SciencesSection of Neuropsychopharmacology, University of CagliariCagliari, Italy[email protected]Search for other works by this author on:
-
CHAPTER 4: Catechol‐O‐Methyl‐Transferase Inhibitors: Present Problems and Relevance of the New Onesp83-109ByP. Nuno Palma;P. Nuno PalmaDepartment of Research & Development, BIAL – Portela & Ca, S.A.À Avenida da Siderurgia Nacional, Mamede do CoronadoPortugalSearch for other works by this author on:László E. Kiss;László E. KissDepartment of Research & Development, BIAL – Portela & Ca, S.A.À Avenida da Siderurgia Nacional, Mamede do CoronadoPortugalSearch for other works by this author on:Patrício Soares‐da‐SilvaPatrício Soares‐da‐SilvaDepartment of Research & Development, BIAL – Portela & Ca, S.A.À Avenida da Siderurgia Nacional, Mamede do CoronadoPortugalDepartment of Pharmacology & Therapeutics, Faculty of MedicineUniversity PortoPorto, Portugal[email protected]Search for other works by this author on:
-
CHAPTER 5: Pharmacologic Management of Dopaminergic‐Induced Dyskinesias in Parkinson’s Diseasep110-125ByMildred D. Gottwald;Mildred D. GottwaldDepartment of Clinical PharmacyUniversity of CaliforniaSan FranciscoUSASearch for other works by this author on:Michael J. AminoffMichael J. AminoffDepartment of NeurologyUniversity of CaliforniaSan FranciscoUSASearch for other works by this author on:
-
CHAPTER 6: D3 Receptor Agonists and Antagonists as Anti‐Parkinsonian Therapeutic Agentsp126-148ByMark Johnson;Mark JohnsonDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy & Health SciencesWayne State UniversityDetroit, USA[email protected]Search for other works by this author on:Aloke DuttaAloke DuttaDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy & Health SciencesWayne State UniversityDetroit, USA[email protected]Search for other works by this author on:
-
CHAPTER 7: Protein Phosphatases in Parkinson’s Diseasep149-171ByPetr HenebergPetr HenebergSearch for other works by this author on:
-
CHAPTER 8: Synuclein and Parkinson’s Disease: An Updatep175-216ByKurt A. JellingerKurt A. JellingerSearch for other works by this author on:
-
CHAPTER 9: New Approaches to Neuroprotection in Parkinson’s Diseasep219-236ByMaría Angeles Mena;María Angeles MenaDepartamento de InvestigaciónUnidad de NeurofarmacologíaMadrid, SpainCentro de Investigación Biomédica en red sobre Enfermedades NeurodegenerativasMadrid, SpainSearch for other works by this author on:Juan Perucho;Juan PeruchoDepartamento de InvestigaciónUnidad de NeurofarmacologíaMadrid, SpainCentro de Investigación Biomédica en red sobre Enfermedades NeurodegenerativasMadrid, SpainSearch for other works by this author on:José Luis López-Sendón;José Luis López-SendónCentro de Investigación Biomédica en red sobre Enfermedades NeurodegenerativasMadrid, SpainSearch for other works by this author on:Justo García de YébenesJusto García de YébenesCentro de Investigación Biomédica en red sobre Enfermedades NeurodegenerativasMadrid, SpainSearch for other works by this author on:
-
CHAPTER 10: Glutamate Receptor Modulators as Emergent Therapeutic Agents in the Treatment of Parkinson’s Diseasep237-265ByIan J. ReynoldsIan J. ReynoldsSearch for other works by this author on:
-
CHAPTER 11: LRRK2 Kinase Inhibitors as New Drugs for Parkinson’s Disease?p266-293BySandra Schulz;Sandra SchulzInstrumental Analysis and BioanalyticsMannheim University of Applied SciencesMannheim, GermanyCenter for Applied Research in Biomedical Mass Spectrometry ABIMASMannheim University of Applied SciencesMannheim, GermanySearch for other works by this author on:Stefan Göring;Stefan GöringClemens Schöpf‐Institute of Organic Chemistry and BiochemistryTechnische Universität DarmstadtDarmstadt, Germanyc.hopf@hs‐mannheim.de; [email protected]Search for other works by this author on:Boris Schmidt;Boris SchmidtClemens Schöpf‐Institute of Organic Chemistry and BiochemistryTechnische Universität DarmstadtDarmstadt, Germanyc.hopf@hs‐mannheim.de; [email protected]Search for other works by this author on:Carsten HopfCarsten HopfInstrumental Analysis and BioanalyticsMannheim University of Applied SciencesMannheim, GermanyCenter for Applied Research in Biomedical Mass Spectrometry ABIMASMannheim University of Applied SciencesMannheim, GermanySearch for other works by this author on:
-
CHAPTER 12: Phosphodiesterase Inhibitors as a New Therapeutic Approach for the Treatment of Parkinson’s Diseasep294-307ByCarmen GilCarmen GilSearch for other works by this author on:
-
CHAPTER 13: 5‐HT1A Receptors as a Therapeutic Target for Parkinson’s Diseasep308-326ByYukihiro OhnoYukihiro OhnoSearch for other works by this author on:
-
CHAPTER 14: Tryptophan Metabolism in Parkinson’s Disease: Future Therapeutic Possibilitiesp327-340ByZsófia Majláth;Zsófia MajláthDepartment of NeurologyUniversity of SzegedSzegedHungarySearch for other works by this author on:László VécseiLászló VécseiDepartment of NeurologyUniversity of SzegedSzegedHungaryNeurology Research Group of the Hungarian Academy of Sciences and University of SzegedSzegedHungary[email protected]‐szeged.huSearch for other works by this author on:
-
CHAPTER 15: Role of P2X7 Receptor Signaling in the Treatment of Parkinson’s Disease and Other Neurodegenerative Disordersp341-360ByTakato Takenouchi;Takato TakenouchiAnimal Immune and Cell Biology Research Unit, Division of Animal SciencesNational Institute of Agrobiological SciencesTsukubaJapan[email protected]Search for other works by this author on:KaZunari Sekiyama;KaZunari SekiyamaDivision of Sensory and Motor SystemsTokyo Metropolitan Institute of Medical ScienceTokyoJapanhashimoto‐[email protected]Search for other works by this author on:Masayo Fujita;Masayo FujitaDivision of Sensory and Motor SystemsTokyo Metropolitan Institute of Medical ScienceTokyoJapanhashimoto‐[email protected]Search for other works by this author on:Shuei Sugama;Shuei SugamaDepartment of PhysiologyNippon Medical SchoolTokyoJapanSearch for other works by this author on:Yoshifumi Iwamaru;Yoshifumi IwamaruPrion Disease Research CenterNational Institute of Animal HealthTsukubaJapanSearch for other works by this author on:Hiroshi Kitani;Hiroshi KitaniAnimal Immune and Cell Biology Research Unit, Division of Animal SciencesNational Institute of Agrobiological SciencesTsukubaJapan[email protected]Search for other works by this author on:Makoto HashimotoMakoto HashimotoDivision of Sensory and Motor SystemsTokyo Metropolitan Institute of Medical ScienceTokyoJapanhashimoto‐[email protected]Search for other works by this author on:
-
CHAPTER 16: Carotid Body Transplants as a Therapy for Parkinson’s Diseasep363-375ByJavier Villadiego;Javier VilladiegoInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaSevillaSpainDepartamento de Fisiología Médica y BiofísicaUniversidad de SevillaSevillaSpainCentro de Investigación Biomédica en Red sobre Enfermedades NeurodegenerativasMadridSpain[email protected]Search for other works by this author on:Ana Belén Muñoz‐Manchado;Ana Belén Muñoz‐ManchadoInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaSevillaSpainDepartamento de Fisiología Médica y BiofísicaUniversidad de SevillaSevillaSpainCentro de Investigación Biomédica en Red sobre Enfermedades NeurodegenerativasMadridSpain[email protected]Present address: Deparment of Medical Biochemistry and Biophysics, Karolinska InstituteStockholmSwedenSearch for other works by this author on:Simón Mendez‐Ferrer;Simón Mendez‐FerrerInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaSevillaSpainDepartamento de Fisiología Médica y BiofísicaUniversidad de SevillaSevillaSpainCentro de Investigación Biomédica en Red sobre Enfermedades NeurodegenerativasMadridSpain[email protected]Present address: Centro Nacional de Investigaciones Cardiovasculares (CNIC), MadridSpain and Icanh School of Medicine at Mount SinaiNew York, USASearch for other works by this author on:Juan José Toledo‐Aral;Juan José Toledo‐AralInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaSevillaSpainDepartamento de Fisiología Médica y BiofísicaUniversidad de SevillaSevillaSpainCentro de Investigación Biomédica en Red sobre Enfermedades NeurodegenerativasMadridSpain[email protected]Search for other works by this author on:José López‐BarneoJosé López‐BarneoInstituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de SevillaSevillaSpainDepartamento de Fisiología Médica y BiofísicaUniversidad de SevillaSevillaSpainCentro de Investigación Biomédica en Red sobre Enfermedades NeurodegenerativasMadridSpain[email protected]Search for other works by this author on:
-
CHAPTER 17: Stem‐Cell‐Based Cell‐Replacement Therapy in Parkinson’s Diseasep376-389ByJan Tønnesen;Jan TønnesenExperimental Epilepsy Group, Division of NeurologyLund University HospitalLundSweden[email protected]Search for other works by this author on:Merab KokaiaMerab KokaiaExperimental Epilepsy Group, Division of NeurologyLund University HospitalLundSweden[email protected]Search for other works by this author on:
Spotlight
Advertisement
Advertisement